nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—FGFR1—lung cancer	0.114	0.308	CbGaD
Ponatinib—SRC—lung cancer	0.0725	0.196	CbGaD
Ponatinib—KDR—lung cancer	0.0681	0.185	CbGaD
Ponatinib—KIT—lung cancer	0.0643	0.174	CbGaD
Ponatinib—TEK—Crizotinib—lung cancer	0.0412	0.108	CbGbCtD
Ponatinib—ABCG2—lung cancer	0.0356	0.0965	CbGaD
Ponatinib—FLT3—Crizotinib—lung cancer	0.0356	0.0933	CbGbCtD
Ponatinib—FLT3—Erlotinib—lung cancer	0.0343	0.09	CbGbCtD
Ponatinib—SRC—Crizotinib—lung cancer	0.0314	0.0825	CbGbCtD
Ponatinib—LYN—Crizotinib—lung cancer	0.0314	0.0825	CbGbCtD
Ponatinib—LCK—Crizotinib—lung cancer	0.0257	0.0675	CbGbCtD
Ponatinib—ABL1—Crizotinib—lung cancer	0.0204	0.0536	CbGbCtD
Ponatinib—ABL1—Erlotinib—lung cancer	0.0197	0.0517	CbGbCtD
Ponatinib—ABCB1—lung cancer	0.0148	0.0401	CbGaD
Ponatinib—ABCB11—Paclitaxel—lung cancer	0.00867	0.0227	CbGbCtD
Ponatinib—ABCG2—Topotecan—lung cancer	0.00832	0.0218	CbGbCtD
Ponatinib—ABCG2—Gefitinib—lung cancer	0.00761	0.02	CbGbCtD
Ponatinib—ABCB11—Vinblastine—lung cancer	0.0076	0.0199	CbGbCtD
Ponatinib—ABCG2—Teniposide—lung cancer	0.00738	0.0194	CbGbCtD
Ponatinib—ABCB11—Doxorubicin—lung cancer	0.00467	0.0123	CbGbCtD
Ponatinib—ABCG2—Erlotinib—lung cancer	0.0045	0.0118	CbGbCtD
Ponatinib—CYP3A5—Gefitinib—lung cancer	0.00422	0.0111	CbGbCtD
Ponatinib—ABCG2—Paclitaxel—lung cancer	0.00412	0.0108	CbGbCtD
Ponatinib—CYP3A5—Teniposide—lung cancer	0.00409	0.0107	CbGbCtD
Ponatinib—ABCG2—Irinotecan—lung cancer	0.00407	0.0107	CbGbCtD
Ponatinib—ABCG2—Cisplatin—lung cancer	0.00331	0.00869	CbGbCtD
Ponatinib—ABCG2—Etoposide—lung cancer	0.00326	0.00854	CbGbCtD
Ponatinib—ABCB1—Topotecan—lung cancer	0.003	0.00787	CbGbCtD
Ponatinib—ABCG2—Docetaxel—lung cancer	0.00298	0.00782	CbGbCtD
Ponatinib—ABCB1—Gefitinib—lung cancer	0.00275	0.0072	CbGbCtD
Ponatinib—CYP2D6—Gefitinib—lung cancer	0.00259	0.00679	CbGbCtD
Ponatinib—CYP3A5—Crizotinib—lung cancer	0.00259	0.00678	CbGbCtD
Ponatinib—CYP3A5—Erlotinib—lung cancer	0.00249	0.00654	CbGbCtD
Ponatinib—CYP2C8—Erlotinib—lung cancer	0.0024	0.00629	CbGbCtD
Ponatinib—CYP3A5—Paclitaxel—lung cancer	0.00228	0.00599	CbGbCtD
Ponatinib—CYP3A5—Irinotecan—lung cancer	0.00225	0.00591	CbGbCtD
Ponatinib—ABCG2—Doxorubicin—lung cancer	0.00222	0.00583	CbGbCtD
Ponatinib—CYP2C8—Paclitaxel—lung cancer	0.0022	0.00576	CbGbCtD
Ponatinib—ABCG2—Methotrexate—lung cancer	0.00215	0.00564	CbGbCtD
Ponatinib—ABCB1—Vinorelbine—lung cancer	0.00211	0.00555	CbGbCtD
Ponatinib—CYP2D6—Vinorelbine—lung cancer	0.00199	0.00523	CbGbCtD
Ponatinib—FGFR4—mammary gland—lung cancer	0.00194	0.0494	CbGeAlD
Ponatinib—CYP3A5—Etoposide—lung cancer	0.0018	0.00473	CbGbCtD
Ponatinib—CYP3A4—Topotecan—lung cancer	0.0018	0.00472	CbGbCtD
Ponatinib—KDR—umbilical vein—lung cancer	0.00178	0.0453	CbGeAlD
Ponatinib—CYP2C8—Etoposide—lung cancer	0.00173	0.00455	CbGbCtD
Ponatinib—ABCB1—Crizotinib—lung cancer	0.00168	0.00441	CbGbCtD
Ponatinib—CYP3A5—Docetaxel—lung cancer	0.00165	0.00433	CbGbCtD
Ponatinib—CYP3A4—Gefitinib—lung cancer	0.00164	0.00432	CbGbCtD
Ponatinib—ABCB1—Gemcitabine—lung cancer	0.00164	0.00431	CbGbCtD
Ponatinib—ABCB1—Erlotinib—lung cancer	0.00162	0.00426	CbGbCtD
Ponatinib—CYP3A4—Teniposide—lung cancer	0.0016	0.00418	CbGbCtD
Ponatinib—CYP2D6—Erlotinib—lung cancer	0.00153	0.00401	CbGbCtD
Ponatinib—ABCB1—Paclitaxel—lung cancer	0.00149	0.0039	CbGbCtD
Ponatinib—ABCB1—Irinotecan—lung cancer	0.00147	0.00385	CbGbCtD
Ponatinib—ABCB1—Vinblastine—lung cancer	0.0013	0.00342	CbGbCtD
Ponatinib—FGFR4—respiratory system—lung cancer	0.00129	0.0329	CbGeAlD
Ponatinib—CYP3A4—Vinorelbine—lung cancer	0.00127	0.00332	CbGbCtD
Ponatinib—CYP2D6—Vinblastine—lung cancer	0.00123	0.00322	CbGbCtD
Ponatinib—ABCB1—Cisplatin—lung cancer	0.0012	0.00313	CbGbCtD
Ponatinib—ABCB1—Etoposide—lung cancer	0.00117	0.00308	CbGbCtD
Ponatinib—BCR—mammary gland—lung cancer	0.00114	0.0292	CbGeAlD
Ponatinib—ABCB1—Docetaxel—lung cancer	0.00107	0.00282	CbGbCtD
Ponatinib—CYP3A4—Crizotinib—lung cancer	0.00101	0.00264	CbGbCtD
Ponatinib—CYP3A4—Erlotinib—lung cancer	0.000973	0.00255	CbGbCtD
Ponatinib—RET—mammary gland—lung cancer	0.000911	0.0232	CbGeAlD
Ponatinib—CYP3A4—Paclitaxel—lung cancer	0.00089	0.00234	CbGbCtD
Ponatinib—FGFR3—respiratory system—lung cancer	0.000881	0.0225	CbGeAlD
Ponatinib—CYP3A4—Irinotecan—lung cancer	0.000878	0.0023	CbGbCtD
Ponatinib—FGFR2—mammary gland—lung cancer	0.000866	0.0221	CbGeAlD
Ponatinib—Nilotinib—FGR—lung cancer	0.000839	0.294	CrCbGaD
Ponatinib—TEK—mammary gland—lung cancer	0.00083	0.0212	CbGeAlD
Ponatinib—FGFR4—Podofilox—Teniposide—lung cancer	0.000803	0.381	CbGdCrCtD
Ponatinib—ABCB1—Doxorubicin—lung cancer	0.000801	0.0021	CbGbCtD
Ponatinib—CYP3A4—Vinblastine—lung cancer	0.000781	0.00205	CbGbCtD
Ponatinib—ABCB1—Methotrexate—lung cancer	0.000776	0.00204	CbGbCtD
Ponatinib—BCR—respiratory system—lung cancer	0.000763	0.0194	CbGeAlD
Ponatinib—FLT3—respiratory system—lung cancer	0.000757	0.0193	CbGeAlD
Ponatinib—CYP2D6—Doxorubicin—lung cancer	0.000755	0.00198	CbGbCtD
Ponatinib—PDGFRA—mammary gland—lung cancer	0.000752	0.0192	CbGeAlD
Ponatinib—FGFR3—epithelium—lung cancer	0.000737	0.0188	CbGeAlD
Ponatinib—FGFR3—bronchus—lung cancer	0.000725	0.0185	CbGeAlD
Ponatinib—CYP3A4—Etoposide—lung cancer	0.000703	0.00185	CbGbCtD
Ponatinib—FGFR4—lung—lung cancer	0.000686	0.0175	CbGeAlD
Ponatinib—KDR—mammary gland—lung cancer	0.000678	0.0173	CbGeAlD
Ponatinib—CYP3A4—Docetaxel—lung cancer	0.000644	0.00169	CbGbCtD
Ponatinib—BCR—bronchus—lung cancer	0.000628	0.016	CbGeAlD
Ponatinib—KIT—mammary gland—lung cancer	0.000601	0.0153	CbGeAlD
Ponatinib—FGFR2—respiratory system—lung cancer	0.000577	0.0147	CbGeAlD
Ponatinib—BCR—trachea—lung cancer	0.000564	0.0144	CbGeAlD
Ponatinib—FGFR1—bronchus—lung cancer	0.000558	0.0142	CbGeAlD
Ponatinib—TEK—respiratory system—lung cancer	0.000553	0.0141	CbGeAlD
Ponatinib—BCR—cardiac atrium—lung cancer	0.000529	0.0135	CbGeAlD
Ponatinib—ABL1—mammary gland—lung cancer	0.000523	0.0133	CbGeAlD
Ponatinib—RET—epithelium—lung cancer	0.000507	0.0129	CbGeAlD
Ponatinib—PDGFRA—respiratory system—lung cancer	0.000501	0.0128	CbGeAlD
Ponatinib—LCK—bronchus—lung cancer	0.0005	0.0127	CbGeAlD
Ponatinib—SRC—respiratory system—lung cancer	0.000491	0.0125	CbGeAlD
Ponatinib—FGFR2—epithelium—lung cancer	0.000482	0.0123	CbGeAlD
Ponatinib—CYP3A4—Doxorubicin—lung cancer	0.00048	0.00126	CbGbCtD
Ponatinib—FGFR4—Podofilox—Etoposide—lung cancer	0.000478	0.226	CbGdCrCtD
Ponatinib—FGFR1—cardiac atrium—lung cancer	0.000471	0.012	CbGeAlD
Ponatinib—FGFR4—lymph node—lung cancer	0.000469	0.012	CbGeAlD
Ponatinib—FGFR3—lung—lung cancer	0.000468	0.0119	CbGeAlD
Ponatinib—TEK—epithelium—lung cancer	0.000462	0.0118	CbGeAlD
Ponatinib—TEK—bronchus—lung cancer	0.000455	0.0116	CbGeAlD
Ponatinib—KDR—respiratory system—lung cancer	0.000452	0.0115	CbGeAlD
Ponatinib—LCK—trachea—lung cancer	0.000449	0.0114	CbGeAlD
Ponatinib—BCR—bone marrow—lung cancer	0.000447	0.0114	CbGeAlD
Ponatinib—FLT3—bone marrow—lung cancer	0.000444	0.0113	CbGeAlD
Ponatinib—Nilotinib—BRAF—lung cancer	0.000441	0.154	CrCbGaD
Ponatinib—FGFR4—Vinblastine—Vinorelbine—lung cancer	0.000411	0.195	CbGdCrCtD
Ponatinib—SRC—epithelium—lung cancer	0.000411	0.0105	CbGeAlD
Ponatinib—BCR—lung—lung cancer	0.000405	0.0103	CbGeAlD
Ponatinib—FLT3—lung—lung cancer	0.000402	0.0102	CbGeAlD
Ponatinib—KIT—respiratory system—lung cancer	0.000401	0.0102	CbGeAlD
Ponatinib—TEK—cardiac atrium—lung cancer	0.000384	0.00979	CbGeAlD
Ponatinib—KDR—epithelium—lung cancer	0.000378	0.00963	CbGeAlD
Ponatinib—KDR—bronchus—lung cancer	0.000372	0.00948	CbGeAlD
Ponatinib—PDGFRA—trachea—lung cancer	0.00037	0.00944	CbGeAlD
Ponatinib—FGFR1—lung—lung cancer	0.00036	0.00918	CbGeAlD
Ponatinib—LCK—bone marrow—lung cancer	0.000356	0.00907	CbGeAlD
Ponatinib—Nilotinib—KIT—lung cancer	0.000354	0.124	CrCbGaD
Ponatinib—ABL1—respiratory system—lung cancer	0.000349	0.00889	CbGeAlD
Ponatinib—Nilotinib—UGT1A1—lung cancer	0.000348	0.122	CrCbGaD
Ponatinib—SRC—cardiac atrium—lung cancer	0.000341	0.00869	CbGeAlD
Ponatinib—CYP2C8—mammary gland—lung cancer	0.000339	0.00865	CbGeAlD
Ponatinib—KIT—epithelium—lung cancer	0.000335	0.00853	CbGeAlD
Ponatinib—KDR—trachea—lung cancer	0.000334	0.00851	CbGeAlD
Ponatinib—KIT—bronchus—lung cancer	0.00033	0.0084	CbGeAlD
Ponatinib—LCK—lung—lung cancer	0.000322	0.00822	CbGeAlD
Ponatinib—KDR—cardiac atrium—lung cancer	0.000314	0.008	CbGeAlD
Ponatinib—FGFR2—lung—lung cancer	0.000306	0.00781	CbGeAlD
Ponatinib—KIT—trachea—lung cancer	0.000296	0.00755	CbGeAlD
Ponatinib—Imatinib—KIT—lung cancer	0.000295	0.103	CrCbGaD
Ponatinib—TEK—lung—lung cancer	0.000294	0.00749	CbGeAlD
Ponatinib—ABL1—bronchus—lung cancer	0.000287	0.00731	CbGeAlD
Ponatinib—BCR—lymph node—lung cancer	0.000277	0.00706	CbGeAlD
Ponatinib—FLT3—lymph node—lung cancer	0.000275	0.00701	CbGeAlD
Ponatinib—PDGFRA—lung—lung cancer	0.000266	0.00678	CbGeAlD
Ponatinib—KDR—bone marrow—lung cancer	0.000265	0.00675	CbGeAlD
Ponatinib—SRC—lung—lung cancer	0.000261	0.00665	CbGeAlD
Ponatinib—ABL1—trachea—lung cancer	0.000258	0.00657	CbGeAlD
Ponatinib—ABL1—Topotecan—Irinotecan—lung cancer	0.000253	0.12	CbGdCrCtD
Ponatinib—FGFR1—lymph node—lung cancer	0.000246	0.00628	CbGeAlD
Ponatinib—ABL1—cardiac atrium—lung cancer	0.000242	0.00617	CbGeAlD
Ponatinib—KDR—lung—lung cancer	0.00024	0.00612	CbGeAlD
Ponatinib—KIT—bone marrow—lung cancer	0.000235	0.00598	CbGeAlD
Ponatinib—RET—lymph node—lung cancer	0.000221	0.00562	CbGeAlD
Ponatinib—LCK—lymph node—lung cancer	0.000221	0.00562	CbGeAlD
Ponatinib—KIT—lung—lung cancer	0.000213	0.00542	CbGeAlD
Ponatinib—ABL1—bone marrow—lung cancer	0.000204	0.00521	CbGeAlD
Ponatinib—CYP3A5—respiratory system—lung cancer	0.000204	0.0052	CbGeAlD
Ponatinib—TEK—lymph node—lung cancer	0.000201	0.00512	CbGeAlD
Ponatinib—Nilotinib—ABCG2—lung cancer	0.000196	0.0685	CrCbGaD
Ponatinib—ABL1—lung—lung cancer	0.000185	0.00472	CbGeAlD
Ponatinib—PDGFRA—lymph node—lung cancer	0.000182	0.00464	CbGeAlD
Ponatinib—SRC—lymph node—lung cancer	0.000178	0.00455	CbGeAlD
Ponatinib—KDR—lymph node—lung cancer	0.000164	0.00418	CbGeAlD
Ponatinib—Imatinib—ABCG2—lung cancer	0.000163	0.0572	CrCbGaD
Ponatinib—KIT—lymph node—lung cancer	0.000145	0.00371	CbGeAlD
Ponatinib—ABCG2—bone marrow—lung cancer	0.000129	0.00328	CbGeAlD
Ponatinib—ABL1—lymph node—lung cancer	0.000127	0.00323	CbGeAlD
Ponatinib—ABCG2—lung—lung cancer	0.000117	0.00298	CbGeAlD
Ponatinib—ABCB1—respiratory system—lung cancer	0.000108	0.00276	CbGeAlD
Ponatinib—CYP3A5—lung—lung cancer	0.000108	0.00276	CbGeAlD
Ponatinib—ABCB1—epithelium—lung cancer	9.06e-05	0.00231	CbGeAlD
Ponatinib—Nilotinib—ABCB1—lung cancer	8.15e-05	0.0285	CrCbGaD
Ponatinib—ABCB1—trachea—lung cancer	8.01e-05	0.00204	CbGeAlD
Ponatinib—ABCG2—lymph node—lung cancer	7.99e-05	0.00204	CbGeAlD
Ponatinib—Imatinib—ALB—lung cancer	7.12e-05	0.0249	CrCbGaD
Ponatinib—Imatinib—ABCB1—lung cancer	6.8e-05	0.0238	CrCbGaD
Ponatinib—ABCB1—bone marrow—lung cancer	6.36e-05	0.00162	CbGeAlD
Ponatinib—ABCB1—lung—lung cancer	5.76e-05	0.00147	CbGeAlD
Ponatinib—ABL1—Epirubicin—Doxorubicin—lung cancer	5.5e-05	0.0261	CbGdCrCtD
Ponatinib—ABL1—Idarubicin—Doxorubicin—lung cancer	5.5e-05	0.0261	CbGdCrCtD
Ponatinib—ABL1—Daunorubicin—Doxorubicin—lung cancer	5.5e-05	0.0261	CbGdCrCtD
Ponatinib—ABCB1—lymph node—lung cancer	3.94e-05	0.001	CbGeAlD
Ponatinib—Dyspnoea—Cisplatin—lung cancer	3.18e-05	0.000328	CcSEcCtD
Ponatinib—Skin disorder—Etoposide—lung cancer	3.18e-05	0.000327	CcSEcCtD
Ponatinib—Erectile dysfunction—Methotrexate—lung cancer	3.17e-05	0.000327	CcSEcCtD
Ponatinib—Dry skin—Doxorubicin—lung cancer	3.16e-05	0.000326	CcSEcCtD
Ponatinib—Hyperhidrosis—Etoposide—lung cancer	3.16e-05	0.000326	CcSEcCtD
Ponatinib—Dizziness—Vinorelbine—lung cancer	3.15e-05	0.000325	CcSEcCtD
Ponatinib—Nervous system disorder—Paclitaxel—lung cancer	3.14e-05	0.000324	CcSEcCtD
Ponatinib—Hypokalaemia—Doxorubicin—lung cancer	3.14e-05	0.000324	CcSEcCtD
Ponatinib—Thrombocytopenia—Paclitaxel—lung cancer	3.14e-05	0.000324	CcSEcCtD
Ponatinib—Breast disorder—Doxorubicin—lung cancer	3.12e-05	0.000321	CcSEcCtD
Ponatinib—Skin disorder—Paclitaxel—lung cancer	3.11e-05	0.000321	CcSEcCtD
Ponatinib—Abdominal pain—Irinotecan—lung cancer	3.11e-05	0.00032	CcSEcCtD
Ponatinib—Body temperature increased—Irinotecan—lung cancer	3.11e-05	0.00032	CcSEcCtD
Ponatinib—Aspartate aminotransferase increased—Doxorubicin—lung cancer	3.11e-05	0.00032	CcSEcCtD
Ponatinib—Decreased appetite—Cisplatin—lung cancer	3.1e-05	0.00032	CcSEcCtD
Ponatinib—Hyperhidrosis—Paclitaxel—lung cancer	3.1e-05	0.00032	CcSEcCtD
Ponatinib—Pneumonia—Methotrexate—lung cancer	3.09e-05	0.000318	CcSEcCtD
Ponatinib—Nasopharyngitis—Doxorubicin—lung cancer	3.09e-05	0.000318	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Cisplatin—lung cancer	3.08e-05	0.000318	CcSEcCtD
Ponatinib—Anaemia—Docetaxel—lung cancer	3.08e-05	0.000317	CcSEcCtD
Ponatinib—Infestation NOS—Methotrexate—lung cancer	3.07e-05	0.000317	CcSEcCtD
Ponatinib—Infestation—Methotrexate—lung cancer	3.07e-05	0.000317	CcSEcCtD
Ponatinib—Pain—Cisplatin—lung cancer	3.05e-05	0.000315	CcSEcCtD
Ponatinib—Alanine aminotransferase increased—Doxorubicin—lung cancer	3.04e-05	0.000314	CcSEcCtD
Ponatinib—Vomiting—Vinorelbine—lung cancer	3.03e-05	0.000312	CcSEcCtD
Ponatinib—Body temperature increased—Gemcitabine—lung cancer	3.03e-05	0.000312	CcSEcCtD
Ponatinib—Rash—Vinorelbine—lung cancer	3.01e-05	0.00031	CcSEcCtD
Ponatinib—Dermatitis—Vinorelbine—lung cancer	3e-05	0.00031	CcSEcCtD
Ponatinib—Abdominal distension—Doxorubicin—lung cancer	3e-05	0.00031	CcSEcCtD
Ponatinib—Stomatitis—Methotrexate—lung cancer	2.99e-05	0.000309	CcSEcCtD
Ponatinib—Headache—Vinorelbine—lung cancer	2.99e-05	0.000308	CcSEcCtD
Ponatinib—Leukopenia—Docetaxel—lung cancer	2.98e-05	0.000307	CcSEcCtD
Ponatinib—Paraesthesia—Etoposide—lung cancer	2.94e-05	0.000303	CcSEcCtD
Ponatinib—Pancreatitis—Doxorubicin—lung cancer	2.92e-05	0.000301	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Paclitaxel—lung cancer	2.92e-05	0.000301	CcSEcCtD
Ponatinib—Dyspnoea—Etoposide—lung cancer	2.92e-05	0.000301	CcSEcCtD
Ponatinib—Cough—Docetaxel—lung cancer	2.91e-05	0.0003	CcSEcCtD
Ponatinib—Angina pectoris—Doxorubicin—lung cancer	2.91e-05	0.000299	CcSEcCtD
Ponatinib—Hepatobiliary disease—Methotrexate—lung cancer	2.9e-05	0.000299	CcSEcCtD
Ponatinib—Insomnia—Paclitaxel—lung cancer	2.9e-05	0.000299	CcSEcCtD
Ponatinib—Epistaxis—Methotrexate—lung cancer	2.9e-05	0.000299	CcSEcCtD
Ponatinib—Paraesthesia—Paclitaxel—lung cancer	2.88e-05	0.000297	CcSEcCtD
Ponatinib—Hypertension—Docetaxel—lung cancer	2.87e-05	0.000296	CcSEcCtD
Ponatinib—Dyspnoea—Paclitaxel—lung cancer	2.86e-05	0.000295	CcSEcCtD
Ponatinib—Decreased appetite—Etoposide—lung cancer	2.84e-05	0.000293	CcSEcCtD
Ponatinib—Arthralgia—Docetaxel—lung cancer	2.83e-05	0.000292	CcSEcCtD
Ponatinib—Myalgia—Docetaxel—lung cancer	2.83e-05	0.000292	CcSEcCtD
Ponatinib—Pancytopenia—Doxorubicin—lung cancer	2.83e-05	0.000292	CcSEcCtD
Ponatinib—Nausea—Vinorelbine—lung cancer	2.83e-05	0.000292	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Etoposide—lung cancer	2.82e-05	0.000291	CcSEcCtD
Ponatinib—Dyspepsia—Paclitaxel—lung cancer	2.82e-05	0.000291	CcSEcCtD
Ponatinib—Body temperature increased—Cisplatin—lung cancer	2.82e-05	0.000291	CcSEcCtD
Ponatinib—Asthenia—Irinotecan—lung cancer	2.82e-05	0.000291	CcSEcCtD
Ponatinib—Fatigue—Etoposide—lung cancer	2.82e-05	0.000291	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	2.82e-05	0.00029	CcSEcCtD
Ponatinib—Pain—Etoposide—lung cancer	2.8e-05	0.000288	CcSEcCtD
Ponatinib—Constipation—Etoposide—lung cancer	2.8e-05	0.000288	CcSEcCtD
Ponatinib—Neutropenia—Doxorubicin—lung cancer	2.79e-05	0.000288	CcSEcCtD
Ponatinib—Decreased appetite—Paclitaxel—lung cancer	2.79e-05	0.000287	CcSEcCtD
Ponatinib—Dry mouth—Docetaxel—lung cancer	2.77e-05	0.000286	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Doxorubicin—lung cancer	2.77e-05	0.000286	CcSEcCtD
Ponatinib—Haemoglobin—Methotrexate—lung cancer	2.77e-05	0.000286	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Paclitaxel—lung cancer	2.77e-05	0.000285	CcSEcCtD
Ponatinib—Fatigue—Paclitaxel—lung cancer	2.76e-05	0.000285	CcSEcCtD
Ponatinib—Haemorrhage—Methotrexate—lung cancer	2.76e-05	0.000284	CcSEcCtD
Ponatinib—Asthenia—Gemcitabine—lung cancer	2.75e-05	0.000283	CcSEcCtD
Ponatinib—Pain—Paclitaxel—lung cancer	2.74e-05	0.000283	CcSEcCtD
Ponatinib—Constipation—Paclitaxel—lung cancer	2.74e-05	0.000283	CcSEcCtD
Ponatinib—Oedema—Docetaxel—lung cancer	2.72e-05	0.00028	CcSEcCtD
Ponatinib—Pruritus—Gemcitabine—lung cancer	2.71e-05	0.000279	CcSEcCtD
Ponatinib—Infection—Docetaxel—lung cancer	2.7e-05	0.000278	CcSEcCtD
Ponatinib—Weight decreased—Doxorubicin—lung cancer	2.7e-05	0.000278	CcSEcCtD
Ponatinib—Hyperglycaemia—Doxorubicin—lung cancer	2.69e-05	0.000277	CcSEcCtD
Ponatinib—Diarrhoea—Irinotecan—lung cancer	2.69e-05	0.000277	CcSEcCtD
Ponatinib—Pneumonia—Doxorubicin—lung cancer	2.67e-05	0.000276	CcSEcCtD
Ponatinib—Gastrointestinal pain—Etoposide—lung cancer	2.67e-05	0.000276	CcSEcCtD
Ponatinib—Nervous system disorder—Docetaxel—lung cancer	2.66e-05	0.000275	CcSEcCtD
Ponatinib—Thrombocytopenia—Docetaxel—lung cancer	2.66e-05	0.000274	CcSEcCtD
Ponatinib—Infestation—Doxorubicin—lung cancer	2.66e-05	0.000274	CcSEcCtD
Ponatinib—Infestation NOS—Doxorubicin—lung cancer	2.66e-05	0.000274	CcSEcCtD
Ponatinib—Visual impairment—Methotrexate—lung cancer	2.66e-05	0.000274	CcSEcCtD
Ponatinib—Skin disorder—Docetaxel—lung cancer	2.64e-05	0.000272	CcSEcCtD
Ponatinib—Gastrointestinal pain—Paclitaxel—lung cancer	2.62e-05	0.00027	CcSEcCtD
Ponatinib—Diarrhoea—Gemcitabine—lung cancer	2.62e-05	0.00027	CcSEcCtD
Ponatinib—Neuropathy peripheral—Doxorubicin—lung cancer	2.61e-05	0.000269	CcSEcCtD
Ponatinib—Dizziness—Irinotecan—lung cancer	2.6e-05	0.000268	CcSEcCtD
Ponatinib—Jaundice—Doxorubicin—lung cancer	2.59e-05	0.000267	CcSEcCtD
Ponatinib—Stomatitis—Doxorubicin—lung cancer	2.59e-05	0.000267	CcSEcCtD
Ponatinib—Body temperature increased—Etoposide—lung cancer	2.58e-05	0.000266	CcSEcCtD
Ponatinib—Abdominal pain—Etoposide—lung cancer	2.58e-05	0.000266	CcSEcCtD
Ponatinib—Urinary tract infection—Doxorubicin—lung cancer	2.58e-05	0.000266	CcSEcCtD
Ponatinib—Eye disorder—Methotrexate—lung cancer	2.58e-05	0.000266	CcSEcCtD
Ponatinib—Asthenia—Cisplatin—lung cancer	2.56e-05	0.000264	CcSEcCtD
Ponatinib—Cardiac disorder—Methotrexate—lung cancer	2.56e-05	0.000264	CcSEcCtD
Ponatinib—Abdominal pain—Paclitaxel—lung cancer	2.53e-05	0.000261	CcSEcCtD
Ponatinib—Body temperature increased—Paclitaxel—lung cancer	2.53e-05	0.000261	CcSEcCtD
Ponatinib—Hepatobiliary disease—Doxorubicin—lung cancer	2.51e-05	0.000259	CcSEcCtD
Ponatinib—Epistaxis—Doxorubicin—lung cancer	2.51e-05	0.000259	CcSEcCtD
Ponatinib—Angiopathy—Methotrexate—lung cancer	2.5e-05	0.000258	CcSEcCtD
Ponatinib—Vomiting—Irinotecan—lung cancer	2.5e-05	0.000258	CcSEcCtD
Ponatinib—Mediastinal disorder—Methotrexate—lung cancer	2.48e-05	0.000256	CcSEcCtD
Ponatinib—Rash—Irinotecan—lung cancer	2.48e-05	0.000256	CcSEcCtD
Ponatinib—Dermatitis—Irinotecan—lung cancer	2.48e-05	0.000255	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Docetaxel—lung cancer	2.48e-05	0.000255	CcSEcCtD
Ponatinib—Chills—Methotrexate—lung cancer	2.47e-05	0.000255	CcSEcCtD
Ponatinib—Headache—Irinotecan—lung cancer	2.46e-05	0.000254	CcSEcCtD
Ponatinib—Insomnia—Docetaxel—lung cancer	2.46e-05	0.000253	CcSEcCtD
Ponatinib—Diarrhoea—Cisplatin—lung cancer	2.44e-05	0.000252	CcSEcCtD
Ponatinib—Paraesthesia—Docetaxel—lung cancer	2.44e-05	0.000252	CcSEcCtD
Ponatinib—Alopecia—Methotrexate—lung cancer	2.44e-05	0.000251	CcSEcCtD
Ponatinib—Vomiting—Gemcitabine—lung cancer	2.43e-05	0.000251	CcSEcCtD
Ponatinib—Dyspnoea—Docetaxel—lung cancer	2.42e-05	0.00025	CcSEcCtD
Ponatinib—Mental disorder—Methotrexate—lung cancer	2.42e-05	0.000249	CcSEcCtD
Ponatinib—Rash—Gemcitabine—lung cancer	2.41e-05	0.000249	CcSEcCtD
Ponatinib—Dermatitis—Gemcitabine—lung cancer	2.41e-05	0.000249	CcSEcCtD
Ponatinib—Malnutrition—Methotrexate—lung cancer	2.4e-05	0.000247	CcSEcCtD
Ponatinib—Erythema—Methotrexate—lung cancer	2.4e-05	0.000247	CcSEcCtD
Ponatinib—Haemoglobin—Doxorubicin—lung cancer	2.4e-05	0.000247	CcSEcCtD
Ponatinib—Headache—Gemcitabine—lung cancer	2.4e-05	0.000247	CcSEcCtD
Ponatinib—Dyspepsia—Docetaxel—lung cancer	2.39e-05	0.000247	CcSEcCtD
Ponatinib—Haemorrhage—Doxorubicin—lung cancer	2.39e-05	0.000246	CcSEcCtD
Ponatinib—Hypoaesthesia—Doxorubicin—lung cancer	2.38e-05	0.000245	CcSEcCtD
Ponatinib—Decreased appetite—Docetaxel—lung cancer	2.36e-05	0.000244	CcSEcCtD
Ponatinib—Oedema peripheral—Doxorubicin—lung cancer	2.35e-05	0.000242	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Docetaxel—lung cancer	2.35e-05	0.000242	CcSEcCtD
Ponatinib—Asthenia—Etoposide—lung cancer	2.35e-05	0.000242	CcSEcCtD
Ponatinib—Connective tissue disorder—Doxorubicin—lung cancer	2.35e-05	0.000242	CcSEcCtD
Ponatinib—Fatigue—Docetaxel—lung cancer	2.34e-05	0.000242	CcSEcCtD
Ponatinib—Nausea—Irinotecan—lung cancer	2.33e-05	0.000241	CcSEcCtD
Ponatinib—Pain—Docetaxel—lung cancer	2.32e-05	0.00024	CcSEcCtD
Ponatinib—Constipation—Docetaxel—lung cancer	2.32e-05	0.00024	CcSEcCtD
Ponatinib—Back pain—Methotrexate—lung cancer	2.32e-05	0.000239	CcSEcCtD
Ponatinib—Pruritus—Etoposide—lung cancer	2.31e-05	0.000238	CcSEcCtD
Ponatinib—Visual impairment—Doxorubicin—lung cancer	2.3e-05	0.000237	CcSEcCtD
Ponatinib—Asthenia—Paclitaxel—lung cancer	2.3e-05	0.000237	CcSEcCtD
Ponatinib—Nausea—Gemcitabine—lung cancer	2.27e-05	0.000234	CcSEcCtD
Ponatinib—Vomiting—Cisplatin—lung cancer	2.27e-05	0.000234	CcSEcCtD
Ponatinib—Pruritus—Paclitaxel—lung cancer	2.27e-05	0.000234	CcSEcCtD
Ponatinib—Vision blurred—Methotrexate—lung cancer	2.26e-05	0.000233	CcSEcCtD
Ponatinib—Rash—Cisplatin—lung cancer	2.25e-05	0.000232	CcSEcCtD
Ponatinib—Dermatitis—Cisplatin—lung cancer	2.25e-05	0.000232	CcSEcCtD
Ponatinib—Diarrhoea—Etoposide—lung cancer	2.24e-05	0.000231	CcSEcCtD
Ponatinib—Eye disorder—Doxorubicin—lung cancer	2.23e-05	0.00023	CcSEcCtD
Ponatinib—Gastrointestinal pain—Docetaxel—lung cancer	2.22e-05	0.000229	CcSEcCtD
Ponatinib—Anaemia—Methotrexate—lung cancer	2.22e-05	0.000229	CcSEcCtD
Ponatinib—Flushing—Doxorubicin—lung cancer	2.22e-05	0.000228	CcSEcCtD
Ponatinib—Cardiac disorder—Doxorubicin—lung cancer	2.22e-05	0.000228	CcSEcCtD
Ponatinib—Diarrhoea—Paclitaxel—lung cancer	2.19e-05	0.000226	CcSEcCtD
Ponatinib—Angiopathy—Doxorubicin—lung cancer	2.17e-05	0.000223	CcSEcCtD
Ponatinib—Dizziness—Etoposide—lung cancer	2.16e-05	0.000223	CcSEcCtD
Ponatinib—Mediastinal disorder—Doxorubicin—lung cancer	2.15e-05	0.000222	CcSEcCtD
Ponatinib—Abdominal pain—Docetaxel—lung cancer	2.15e-05	0.000221	CcSEcCtD
Ponatinib—Body temperature increased—Docetaxel—lung cancer	2.15e-05	0.000221	CcSEcCtD
Ponatinib—Leukopenia—Methotrexate—lung cancer	2.15e-05	0.000221	CcSEcCtD
Ponatinib—Chills—Doxorubicin—lung cancer	2.14e-05	0.000221	CcSEcCtD
Ponatinib—Arrhythmia—Doxorubicin—lung cancer	2.13e-05	0.00022	CcSEcCtD
Ponatinib—Dizziness—Paclitaxel—lung cancer	2.12e-05	0.000219	CcSEcCtD
Ponatinib—Nausea—Cisplatin—lung cancer	2.12e-05	0.000219	CcSEcCtD
Ponatinib—Alopecia—Doxorubicin—lung cancer	2.11e-05	0.000217	CcSEcCtD
Ponatinib—Cough—Methotrexate—lung cancer	2.09e-05	0.000216	CcSEcCtD
Ponatinib—Mental disorder—Doxorubicin—lung cancer	2.09e-05	0.000216	CcSEcCtD
Ponatinib—Vomiting—Etoposide—lung cancer	2.08e-05	0.000214	CcSEcCtD
Ponatinib—Malnutrition—Doxorubicin—lung cancer	2.08e-05	0.000214	CcSEcCtD
Ponatinib—Erythema—Doxorubicin—lung cancer	2.08e-05	0.000214	CcSEcCtD
Ponatinib—Rash—Etoposide—lung cancer	2.06e-05	0.000213	CcSEcCtD
Ponatinib—Dermatitis—Etoposide—lung cancer	2.06e-05	0.000212	CcSEcCtD
Ponatinib—Headache—Etoposide—lung cancer	2.05e-05	0.000211	CcSEcCtD
Ponatinib—Arthralgia—Methotrexate—lung cancer	2.04e-05	0.000211	CcSEcCtD
Ponatinib—Myalgia—Methotrexate—lung cancer	2.04e-05	0.000211	CcSEcCtD
Ponatinib—Vomiting—Paclitaxel—lung cancer	2.04e-05	0.00021	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	2.03e-05	0.000209	CcSEcCtD
Ponatinib—Rash—Paclitaxel—lung cancer	2.02e-05	0.000208	CcSEcCtD
Ponatinib—Dermatitis—Paclitaxel—lung cancer	2.02e-05	0.000208	CcSEcCtD
Ponatinib—Back pain—Doxorubicin—lung cancer	2.01e-05	0.000207	CcSEcCtD
Ponatinib—Headache—Paclitaxel—lung cancer	2.01e-05	0.000207	CcSEcCtD
Ponatinib—Muscle spasms—Doxorubicin—lung cancer	2e-05	0.000206	CcSEcCtD
Ponatinib—Vision blurred—Doxorubicin—lung cancer	1.96e-05	0.000202	CcSEcCtD
Ponatinib—Asthenia—Docetaxel—lung cancer	1.95e-05	0.000201	CcSEcCtD
Ponatinib—Infection—Methotrexate—lung cancer	1.95e-05	0.000201	CcSEcCtD
Ponatinib—Nausea—Etoposide—lung cancer	1.94e-05	0.0002	CcSEcCtD
Ponatinib—Pruritus—Docetaxel—lung cancer	1.92e-05	0.000198	CcSEcCtD
Ponatinib—Nervous system disorder—Methotrexate—lung cancer	1.92e-05	0.000198	CcSEcCtD
Ponatinib—Anaemia—Doxorubicin—lung cancer	1.92e-05	0.000198	CcSEcCtD
Ponatinib—Thrombocytopenia—Methotrexate—lung cancer	1.92e-05	0.000198	CcSEcCtD
Ponatinib—Nausea—Paclitaxel—lung cancer	1.9e-05	0.000196	CcSEcCtD
Ponatinib—Skin disorder—Methotrexate—lung cancer	1.9e-05	0.000196	CcSEcCtD
Ponatinib—Hyperhidrosis—Methotrexate—lung cancer	1.89e-05	0.000195	CcSEcCtD
Ponatinib—Leukopenia—Doxorubicin—lung cancer	1.86e-05	0.000192	CcSEcCtD
Ponatinib—Diarrhoea—Docetaxel—lung cancer	1.86e-05	0.000192	CcSEcCtD
Ponatinib—Cough—Doxorubicin—lung cancer	1.81e-05	0.000187	CcSEcCtD
Ponatinib—Dizziness—Docetaxel—lung cancer	1.8e-05	0.000185	CcSEcCtD
Ponatinib—Hypertension—Doxorubicin—lung cancer	1.79e-05	0.000185	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Methotrexate—lung cancer	1.78e-05	0.000184	CcSEcCtD
Ponatinib—Insomnia—Methotrexate—lung cancer	1.77e-05	0.000183	CcSEcCtD
Ponatinib—Myalgia—Doxorubicin—lung cancer	1.77e-05	0.000182	CcSEcCtD
Ponatinib—Arthralgia—Doxorubicin—lung cancer	1.77e-05	0.000182	CcSEcCtD
Ponatinib—Paraesthesia—Methotrexate—lung cancer	1.76e-05	0.000181	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	1.76e-05	0.000181	CcSEcCtD
Ponatinib—Dyspnoea—Methotrexate—lung cancer	1.75e-05	0.00018	CcSEcCtD
Ponatinib—Dry mouth—Doxorubicin—lung cancer	1.73e-05	0.000178	CcSEcCtD
Ponatinib—Vomiting—Docetaxel—lung cancer	1.73e-05	0.000178	CcSEcCtD
Ponatinib—Dyspepsia—Methotrexate—lung cancer	1.72e-05	0.000178	CcSEcCtD
Ponatinib—Rash—Docetaxel—lung cancer	1.71e-05	0.000177	CcSEcCtD
Ponatinib—Dermatitis—Docetaxel—lung cancer	1.71e-05	0.000176	CcSEcCtD
Ponatinib—Decreased appetite—Methotrexate—lung cancer	1.7e-05	0.000176	CcSEcCtD
Ponatinib—Headache—Docetaxel—lung cancer	1.7e-05	0.000176	CcSEcCtD
Ponatinib—Oedema—Doxorubicin—lung cancer	1.7e-05	0.000175	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Methotrexate—lung cancer	1.69e-05	0.000174	CcSEcCtD
Ponatinib—Fatigue—Methotrexate—lung cancer	1.69e-05	0.000174	CcSEcCtD
Ponatinib—Infection—Doxorubicin—lung cancer	1.68e-05	0.000174	CcSEcCtD
Ponatinib—Pain—Methotrexate—lung cancer	1.67e-05	0.000173	CcSEcCtD
Ponatinib—Nervous system disorder—Doxorubicin—lung cancer	1.66e-05	0.000171	CcSEcCtD
Ponatinib—Thrombocytopenia—Doxorubicin—lung cancer	1.66e-05	0.000171	CcSEcCtD
Ponatinib—Skin disorder—Doxorubicin—lung cancer	1.65e-05	0.00017	CcSEcCtD
Ponatinib—Hyperhidrosis—Doxorubicin—lung cancer	1.64e-05	0.000169	CcSEcCtD
Ponatinib—Nausea—Docetaxel—lung cancer	1.61e-05	0.000166	CcSEcCtD
Ponatinib—Gastrointestinal pain—Methotrexate—lung cancer	1.6e-05	0.000165	CcSEcCtD
Ponatinib—Abdominal pain—Methotrexate—lung cancer	1.55e-05	0.00016	CcSEcCtD
Ponatinib—Body temperature increased—Methotrexate—lung cancer	1.55e-05	0.00016	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Doxorubicin—lung cancer	1.55e-05	0.000159	CcSEcCtD
Ponatinib—Insomnia—Doxorubicin—lung cancer	1.53e-05	0.000158	CcSEcCtD
Ponatinib—Paraesthesia—Doxorubicin—lung cancer	1.52e-05	0.000157	CcSEcCtD
Ponatinib—Dyspnoea—Doxorubicin—lung cancer	1.51e-05	0.000156	CcSEcCtD
Ponatinib—Dyspepsia—Doxorubicin—lung cancer	1.49e-05	0.000154	CcSEcCtD
Ponatinib—Decreased appetite—Doxorubicin—lung cancer	1.47e-05	0.000152	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Doxorubicin—lung cancer	1.46e-05	0.000151	CcSEcCtD
Ponatinib—Fatigue—Doxorubicin—lung cancer	1.46e-05	0.000151	CcSEcCtD
Ponatinib—Pain—Doxorubicin—lung cancer	1.45e-05	0.00015	CcSEcCtD
Ponatinib—Constipation—Doxorubicin—lung cancer	1.45e-05	0.00015	CcSEcCtD
Ponatinib—Asthenia—Methotrexate—lung cancer	1.41e-05	0.000145	CcSEcCtD
Ponatinib—Gastrointestinal pain—Doxorubicin—lung cancer	1.39e-05	0.000143	CcSEcCtD
Ponatinib—Pruritus—Methotrexate—lung cancer	1.39e-05	0.000143	CcSEcCtD
Ponatinib—Abdominal pain—Doxorubicin—lung cancer	1.34e-05	0.000138	CcSEcCtD
Ponatinib—Body temperature increased—Doxorubicin—lung cancer	1.34e-05	0.000138	CcSEcCtD
Ponatinib—Diarrhoea—Methotrexate—lung cancer	1.34e-05	0.000138	CcSEcCtD
Ponatinib—Dizziness—Methotrexate—lung cancer	1.3e-05	0.000134	CcSEcCtD
Ponatinib—Vomiting—Methotrexate—lung cancer	1.25e-05	0.000128	CcSEcCtD
Ponatinib—Rash—Methotrexate—lung cancer	1.23e-05	0.000127	CcSEcCtD
Ponatinib—Dermatitis—Methotrexate—lung cancer	1.23e-05	0.000127	CcSEcCtD
Ponatinib—Headache—Methotrexate—lung cancer	1.23e-05	0.000126	CcSEcCtD
Ponatinib—Asthenia—Doxorubicin—lung cancer	1.22e-05	0.000125	CcSEcCtD
Ponatinib—Pruritus—Doxorubicin—lung cancer	1.2e-05	0.000124	CcSEcCtD
Ponatinib—Nausea—Methotrexate—lung cancer	1.16e-05	0.00012	CcSEcCtD
Ponatinib—Diarrhoea—Doxorubicin—lung cancer	1.16e-05	0.00012	CcSEcCtD
Ponatinib—Dizziness—Doxorubicin—lung cancer	1.12e-05	0.000116	CcSEcCtD
Ponatinib—Vomiting—Doxorubicin—lung cancer	1.08e-05	0.000111	CcSEcCtD
Ponatinib—Rash—Doxorubicin—lung cancer	1.07e-05	0.00011	CcSEcCtD
Ponatinib—Dermatitis—Doxorubicin—lung cancer	1.07e-05	0.00011	CcSEcCtD
Ponatinib—Headache—Doxorubicin—lung cancer	1.06e-05	0.00011	CcSEcCtD
Ponatinib—Nausea—Doxorubicin—lung cancer	1.01e-05	0.000104	CcSEcCtD
Ponatinib—KIT—Signaling Pathways—MAPK3—lung cancer	6.15e-07	5.67e-06	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—AKT1—lung cancer	6.14e-07	5.66e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL6R—lung cancer	6.12e-07	5.64e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—STAT3—lung cancer	6.11e-07	5.63e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CREBBP—lung cancer	6.11e-07	5.63e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—NRAS—lung cancer	6.1e-07	5.62e-06	CbGpPWpGaD
Ponatinib—FGFR1—Disease—IL6—lung cancer	6.1e-07	5.62e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—STAT3—lung cancer	6.1e-07	5.61e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ABCB1—lung cancer	6.1e-07	5.61e-06	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—PIK3CA—lung cancer	6.09e-07	5.61e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MYC—lung cancer	6.09e-07	5.61e-06	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—AKT1—lung cancer	6.09e-07	5.61e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—NRAS—lung cancer	6.08e-07	5.6e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—IL6—lung cancer	6.08e-07	5.6e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—AKT1—lung cancer	6.08e-07	5.6e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTT1—lung cancer	6.07e-07	5.59e-06	CbGpPWpGaD
Ponatinib—LYN—Immune System—HRAS—lung cancer	6.07e-07	5.59e-06	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—HRAS—lung cancer	6.06e-07	5.58e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MMP9—lung cancer	6.05e-07	5.57e-06	CbGpPWpGaD
Ponatinib—ABL1—Immune System—HRAS—lung cancer	6.04e-07	5.56e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—STAT3—lung cancer	6.04e-07	5.56e-06	CbGpPWpGaD
Ponatinib—FGFR2—Disease—AKT1—lung cancer	6.04e-07	5.56e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CDKN1A—lung cancer	6.03e-07	5.55e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—NRAS—lung cancer	6.02e-07	5.55e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—MAPK3—lung cancer	6.01e-07	5.54e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PTEN—lung cancer	6.01e-07	5.54e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GCLC—lung cancer	6e-07	5.53e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP2A6—lung cancer	6e-07	5.53e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—TYMS—lung cancer	5.99e-07	5.51e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MYC—lung cancer	5.99e-07	5.51e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—EGFR—lung cancer	5.96e-07	5.49e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CYP1A1—lung cancer	5.95e-07	5.48e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—EP300—lung cancer	5.94e-07	5.47e-06	CbGpPWpGaD
Ponatinib—KIT—Disease—AKT1—lung cancer	5.93e-07	5.46e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GSTM1—lung cancer	5.92e-07	5.45e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ERCC2—lung cancer	5.9e-07	5.44e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—POMC—lung cancer	5.88e-07	5.42e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MDM2—lung cancer	5.86e-07	5.4e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—APOA1—lung cancer	5.86e-07	5.4e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—EGFR—lung cancer	5.85e-07	5.39e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—KRAS—lung cancer	5.85e-07	5.39e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—MYC—lung cancer	5.85e-07	5.39e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—RAF1—lung cancer	5.84e-07	5.38e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MAPK3—lung cancer	5.84e-07	5.38e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MAP2K1—lung cancer	5.83e-07	5.37e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MAPK3—lung cancer	5.83e-07	5.36e-06	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL6—lung cancer	5.81e-07	5.35e-06	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—IL6—lung cancer	5.8e-07	5.34e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CD—lung cancer	5.79e-07	5.34e-06	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL6—lung cancer	5.78e-07	5.33e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—ERBB2—lung cancer	5.78e-07	5.32e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—MAPK3—lung cancer	5.77e-07	5.31e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—EP300—lung cancer	5.73e-07	5.28e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CREBBP—lung cancer	5.73e-07	5.28e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—EGFR—lung cancer	5.72e-07	5.27e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PTEN—lung cancer	5.71e-07	5.26e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PIK3CB—lung cancer	5.7e-07	5.25e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MTOR—lung cancer	5.7e-07	5.25e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ENO1—lung cancer	5.69e-07	5.24e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MYC—lung cancer	5.68e-07	5.23e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MYC—lung cancer	5.67e-07	5.22e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—KRAS—lung cancer	5.63e-07	5.19e-06	CbGpPWpGaD
Ponatinib—FGFR1—Disease—AKT1—lung cancer	5.63e-07	5.18e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	5.61e-07	5.17e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—AKT1—lung cancer	5.61e-07	5.17e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CYP1A1—lung cancer	5.61e-07	5.17e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—SRC—lung cancer	5.58e-07	5.14e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—STAT3—lung cancer	5.57e-07	5.13e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ERCC2—lung cancer	5.56e-07	5.12e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—NRAS—lung cancer	5.56e-07	5.12e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—EGFR—lung cancer	5.56e-07	5.12e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—EGFR—lung cancer	5.54e-07	5.1e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—KRAS—lung cancer	5.53e-07	5.09e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—EGFR—lung cancer	5.49e-07	5.05e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CXCL8—lung cancer	5.48e-07	5.05e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—EP300—lung cancer	5.45e-07	5.02e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CD—lung cancer	5.43e-07	5e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—VEGFA—lung cancer	5.43e-07	5e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—KRAS—lung cancer	5.4e-07	4.98e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—PIK3CA—lung cancer	5.38e-07	4.95e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—STAT3—lung cancer	5.38e-07	4.95e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NRAS—lung cancer	5.36e-07	4.94e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—ALB—lung cancer	5.36e-07	4.94e-06	CbGpPWpGaD
Ponatinib—LYN—Immune System—AKT1—lung cancer	5.36e-07	4.94e-06	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—AKT1—lung cancer	5.35e-07	4.93e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CG—lung cancer	5.35e-07	4.93e-06	CbGpPWpGaD
Ponatinib—ABL1—Immune System—AKT1—lung cancer	5.34e-07	4.91e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—MAPK3—lung cancer	5.32e-07	4.9e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—KRAS—lung cancer	5.25e-07	4.83e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CASP3—lung cancer	5.25e-07	4.83e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL2—lung cancer	5.24e-07	4.82e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—KRAS—lung cancer	5.24e-07	4.82e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MDM2—lung cancer	5.19e-07	4.78e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—KRAS—lung cancer	5.18e-07	4.77e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—MYC—lung cancer	5.18e-07	4.77e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—PIK3CA—lung cancer	5.17e-07	4.76e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—RAF1—lung cancer	5.17e-07	4.76e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MAPK3—lung cancer	5.14e-07	4.73e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ERBB2—lung cancer	5.12e-07	4.71e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—APOA1—lung cancer	5.11e-07	4.7e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCND1—lung cancer	5.11e-07	4.7e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP2E1—lung cancer	5.11e-07	4.7e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—JUN—lung cancer	5.1e-07	4.69e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—POMC—lung cancer	5.09e-07	4.69e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—PIK3CA—lung cancer	5.08e-07	4.68e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—EGFR—lung cancer	5.06e-07	4.66e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MTOR—lung cancer	5.05e-07	4.65e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CB—lung cancer	5.05e-07	4.65e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—NQO1—lung cancer	5.05e-07	4.65e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TP53—lung cancer	5e-07	4.61e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MYC—lung cancer	5e-07	4.6e-06	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—AKT1—lung cancer	4.98e-07	4.58e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—HRAS—lung cancer	4.98e-07	4.58e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—PIK3CA—lung cancer	4.97e-07	4.57e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CREBBP—lung cancer	4.96e-07	4.57e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MMP9—lung cancer	4.96e-07	4.57e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CDKN1A—lung cancer	4.94e-07	4.55e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PTEN—lung cancer	4.93e-07	4.54e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TP53—lung cancer	4.92e-07	4.53e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—EGFR—lung cancer	4.89e-07	4.5e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CXCL8—lung cancer	4.85e-07	4.47e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—PIK3CA—lung cancer	4.82e-07	4.44e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—APOA1—lung cancer	4.81e-07	4.43e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—PIK3CA—lung cancer	4.81e-07	4.43e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—HRAS—lung cancer	4.79e-07	4.41e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—KRAS—lung cancer	4.78e-07	4.41e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL6—lung cancer	4.76e-07	4.39e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—PIK3CA—lung cancer	4.76e-07	4.38e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CB—lung cancer	4.73e-07	4.36e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CD—lung cancer	4.71e-07	4.33e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—HRAS—lung cancer	4.7e-07	4.33e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—EP300—lung cancer	4.7e-07	4.33e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTGS2—lung cancer	4.69e-07	4.32e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TP53—lung cancer	4.66e-07	4.3e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CG—lung cancer	4.66e-07	4.29e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TP53—lung cancer	4.65e-07	4.28e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ALB—lung cancer	4.64e-07	4.28e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CASP3—lung cancer	4.64e-07	4.28e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL2—lung cancer	4.64e-07	4.27e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—KRAS—lung cancer	4.62e-07	4.25e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—HRAS—lung cancer	4.59e-07	4.23e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IL6—lung cancer	4.58e-07	4.22e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—SRC—lung cancer	4.57e-07	4.21e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—STK11—lung cancer	4.55e-07	4.19e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCND1—lung cancer	4.52e-07	4.16e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—JUN—lung cancer	4.51e-07	4.15e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IL6—lung cancer	4.5e-07	4.14e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—HRAS—lung cancer	4.46e-07	4.11e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—VEGFA—lung cancer	4.45e-07	4.1e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—HRAS—lung cancer	4.45e-07	4.1e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—POMC—lung cancer	4.44e-07	4.09e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—STAT3—lung cancer	4.41e-07	4.06e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—HRAS—lung cancer	4.41e-07	4.06e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NRAS—lung cancer	4.4e-07	4.05e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—IL6—lung cancer	4.4e-07	4.05e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—PIK3CA—lung cancer	4.4e-07	4.05e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CG—lung cancer	4.39e-07	4.05e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—AKT1—lung cancer	4.39e-07	4.05e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MMP9—lung cancer	4.39e-07	4.04e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CDKN1A—lung cancer	4.37e-07	4.03e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PTEN—lung cancer	4.36e-07	4.02e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CREBBP—lung cancer	4.32e-07	3.98e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL6—lung cancer	4.27e-07	3.93e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL6—lung cancer	4.26e-07	3.92e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PIK3CA—lung cancer	4.24e-07	3.91e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—AKT1—lung cancer	4.23e-07	3.89e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL6—lung cancer	4.22e-07	3.88e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MAPK3—lung cancer	4.21e-07	3.88e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTP1—lung cancer	4.21e-07	3.88e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—POMC—lung cancer	4.18e-07	3.85e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—EP300—lung cancer	4.16e-07	3.83e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—AKT1—lung cancer	4.15e-07	3.82e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TP53—lung cancer	4.1e-07	3.78e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CB—lung cancer	4.1e-07	3.78e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CD—lung cancer	4.1e-07	3.77e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CAT—lung cancer	4.1e-07	3.77e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MYC—lung cancer	4.1e-07	3.77e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTEN—lung cancer	4.09e-07	3.77e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CREBBP—lung cancer	4.07e-07	3.75e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—HRAS—lung cancer	4.07e-07	3.75e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTGS2—lung cancer	4.06e-07	3.74e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—AKT1—lung cancer	4.06e-07	3.74e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ALB—lung cancer	4.05e-07	3.73e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PIK3CA—lung cancer	4.03e-07	3.71e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—EGFR—lung cancer	4.01e-07	3.69e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ABCB1—lung cancer	3.99e-07	3.67e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—VEGFA—lung cancer	3.94e-07	3.63e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—AKT1—lung cancer	3.94e-07	3.63e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—AKT1—lung cancer	3.93e-07	3.62e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—HRAS—lung cancer	3.92e-07	3.61e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—TYMS—lung cancer	3.91e-07	3.6e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—STAT3—lung cancer	3.9e-07	3.59e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—EP300—lung cancer	3.9e-07	3.59e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NRAS—lung cancer	3.89e-07	3.59e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—IL6—lung cancer	3.89e-07	3.58e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—AKT1—lung cancer	3.89e-07	3.58e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTM1—lung cancer	3.87e-07	3.56e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CD—lung cancer	3.86e-07	3.56e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ALB—lung cancer	3.81e-07	3.51e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—KRAS—lung cancer	3.78e-07	3.49e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL6—lung cancer	3.76e-07	3.46e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MAPK3—lung cancer	3.73e-07	3.43e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP1A1—lung cancer	3.67e-07	3.38e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ERCC2—lung cancer	3.64e-07	3.35e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MYC—lung cancer	3.63e-07	3.34e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—AKT1—lung cancer	3.59e-07	3.31e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CB—lung cancer	3.57e-07	3.29e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—EGFR—lung cancer	3.55e-07	3.27e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTEN—lung cancer	3.54e-07	3.26e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTGS2—lung cancer	3.54e-07	3.26e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PIK3CA—lung cancer	3.48e-07	3.2e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—AKT1—lung cancer	3.47e-07	3.19e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—EP300—lung cancer	3.38e-07	3.11e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CB—lung cancer	3.37e-07	3.1e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TP53—lung cancer	3.36e-07	3.1e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KRAS—lung cancer	3.35e-07	3.09e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTGS2—lung cancer	3.34e-07	3.07e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—AKT1—lung cancer	3.29e-07	3.03e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—HRAS—lung cancer	3.22e-07	2.96e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—APOA1—lung cancer	3.15e-07	2.9e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTEN—lung cancer	3.09e-07	2.84e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL6—lung cancer	3.08e-07	2.84e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CA—lung cancer	3.08e-07	2.83e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TP53—lung cancer	2.98e-07	2.74e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—EP300—lung cancer	2.94e-07	2.71e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTEN—lung cancer	2.91e-07	2.68e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CA—lung cancer	2.89e-07	2.66e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CG—lung cancer	2.87e-07	2.65e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—HRAS—lung cancer	2.85e-07	2.62e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—AKT1—lung cancer	2.84e-07	2.62e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—EP300—lung cancer	2.77e-07	2.56e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—POMC—lung cancer	2.73e-07	2.52e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL6—lung cancer	2.73e-07	2.51e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CREBBP—lung cancer	2.66e-07	2.45e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CD—lung cancer	2.53e-07	2.33e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AKT1—lung cancer	2.51e-07	2.32e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CA—lung cancer	2.5e-07	2.3e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ALB—lung cancer	2.49e-07	2.3e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—AKT1—lung cancer	2.36e-07	2.17e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CB—lung cancer	2.2e-07	2.03e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTGS2—lung cancer	2.18e-07	2.01e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CA—lung cancer	2.18e-07	2.01e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CA—lung cancer	2.05e-07	1.89e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—AKT1—lung cancer	2.04e-07	1.88e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTEN—lung cancer	1.9e-07	1.75e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—EP300—lung cancer	1.81e-07	1.67e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—AKT1—lung cancer	1.78e-07	1.64e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—AKT1—lung cancer	1.68e-07	1.54e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CA—lung cancer	1.34e-07	1.24e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AKT1—lung cancer	1.1e-07	1.01e-06	CbGpPWpGaD
